Leap Therapeutics
Leap Therapeutics is a biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics, with its most advanced clinical candidate being DKN-01, a monoclonal antibody targeting the DKK1 protein.
Company Overview
Leap Therapeutics, located at 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141, USA, specializes in developing targeted and immuno-oncology therapeutics. The company focuses on creating novel treatments for various cancers, leveraging its expertise in monoclonal antibodies to address significant unmet medical needs.
DKN-01
DKN-01 is Leap Therapeutics' most advanced clinical candidate. It is a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein. DKN-01 is being developed for patients with esophagogastric, gynecologic, and colorectal cancers. It has shown significant tumor reductions in preclinical models of non-small cell lung cancer (NSCLC) and is being evaluated in combination with chemotherapies, PD-1 antibody immune checkpoint inhibitors, and other treatments across various phases of clinical trials for gastric cancer, colorectal cancer, endometrial cancer, and metastatic castration-resistant prostate cancer (mCRPC).
FL-301
FL-301 is another significant therapeutic candidate from Leap Therapeutics. This humanized monoclonal antibody targets Claudin18.2 and is being developed for gastric and pancreatic cancer patients. FL-301 has demonstrated a 10-20x higher affinity to Claudin18.2 compared to the benchmark antibody zolbetuximab. It is also being evaluated in a multicenter, open-label phase I clinical trial for patients with CLDN18.2-positive advanced solid tumors.
Preclinical Antibody Programs
Leap Therapeutics has multiple preclinical programs targeting Claudin18.2/CD137 and GDF15. FL-302 is a tetravalent bispecific antibody targeting both Claudin18.2 and CD137 (4-1BB), while FL-501 is designed to neutralize GDF15 and prevent its receptor binding. These programs represent the company's efforts to expand its pipeline and develop next-generation cancer therapies.
Recent Developments
In recent developments, Leap Therapeutics announced a $40 million private placement in April 2024. The company also participated in the 42nd Annual J.P. Morgan Healthcare Conference in January 2024, signaling its active engagement with the healthcare investment community and stakeholders.